Published in J Mol Biol on February 28, 2013
The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res (2014) 1.07
Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412-423. PLoS Pathog (2014) 0.96
Use of host-like peptide motifs in viral proteins is a prevalent strategy in host-virus interactions. Cell Rep (2014) 0.95
Structural and antigenic definition of hepatitis C virus E2 glycoprotein epitopes targeted by monoclonal antibodies. Clin Dev Immunol (2013) 0.95
Structural flexibility of a conserved antigenic region in hepatitis C virus glycoprotein E2 recognized by broadly neutralizing antibodies. J Virol (2014) 0.95
Framework selection can influence pharmacokinetics of a humanized therapeutic antibody through differences in molecule charge. MAbs (2014) 0.94
Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain. J Virol (2014) 0.87
Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design. Curr Opin Virol (2015) 0.86
Genetic Diversity and Selective Pressure in Hepatitis C Virus Genotypes 1-6: Significance for Direct-Acting Antiviral Treatment and Drug Resistance. Viruses (2015) 0.86
Antibody Response to Hypervariable Region 1 Interferes with Broadly Neutralizing Antibodies to Hepatitis C Virus. J Virol (2016) 0.85
Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody. J Biol Chem (2015) 0.85
Genetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine Design. Viruses (2015) 0.84
Analysis of the evolution and structure of a complex intrahost viral population in chronic hepatitis C virus mapped by ultradeep pyrosequencing. J Virol (2014) 0.83
A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance. J Virol (2015) 0.83
Generation and Characterization of Monoclonal Antibodies against a Cyclic Variant of Hepatitis C Virus E2 Epitope 412-422. J Virol (2016) 0.81
High-throughput sequencing analysis of post-liver transplantation HCV E2 glycoprotein evolution in the presence and absence of neutralizing monoclonal antibody. PLoS One (2014) 0.80
Approaching rational epitope vaccine design for hepatitis C virus with meta-server and multivalent scaffolding. Sci Rep (2015) 0.80
HCV E2 core structures and mAbs: something is still missing. Drug Discov Today (2014) 0.79
Evaluating the Use of Antibody Variable Region (Fv) Charge as a Risk Assessment Tool for Predicting Typical Cynomolgus Monkey Pharmacokinetics. J Biol Chem (2015) 0.79
Immunoglobulin with High-Titer In Vitro Cross-Neutralizing Hepatitis C Virus Antibodies Passively Protects Chimpanzees from Homologous, but Not Heterologous, Challenge. J Virol (2015) 0.78
Viral evasion and challenges of hepatitis C virus vaccine development. Curr Opin Virol (2016) 0.77
Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies. Expert Rev Vaccines (2016) 0.77
Global mapping of antibody recognition of the hepatitis C virus E2 glycoprotein: Implications for vaccine design. Proc Natl Acad Sci U S A (2016) 0.77
Structural flexibility at a major conserved antibody target on hepatitis C virus E2 antigen. Proc Natl Acad Sci U S A (2016) 0.77
Hepatitis C Virus Resistance to Carbohydrate-Binding Agents. PLoS One (2016) 0.76
The core domain of hepatitis C virus glycoprotein E2 generates potent cross-neutralizing antibodies in guinea pigs. Hepatology (2017) 0.76
Longitudinal Sequence and Functional Evolution within Glycoprotein E2 in Hepatitis C Virus Genotype 3a Infection. PLoS One (2015) 0.76
Role of Conserved E2 Residue W420 in Receptor Binding and Hepatitis C Virus Infection. J Virol (2016) 0.76
Conformational Flexibility in the Immunoglobulin-Like Domain of the Hepatitis C Virus Glycoprotein E2. MBio (2017) 0.75
Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1. PLoS Pathog (2017) 0.75
Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection. Infect Genet Evol (2017) 0.75
Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A. PLoS Pathog (2017) 0.75
Immune Evasion Strategies during Chronic Hepatitis B and C Virus Infection. Vaccines (Basel) (2017) 0.75
Structure-Based Design of Hepatitis C Virus Vaccines that Elicit Neutralizing Antibody Responses to a Conserved Epitope. J Virol (2017) 0.75
Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. Nat Med (2011) 6.21
LMSD: LIPID MAPS structure database. Nucleic Acids Res (2006) 6.21
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem (2002) 5.63
Ubiquitin chain editing revealed by polyubiquitin linkage-specific antibodies. Cell (2008) 5.37
An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell (2003) 5.06
The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature (2004) 5.05
Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature (2003) 3.96
DUBA: a deubiquitinase that regulates type I interferon production. Science (2007) 3.88
Human De-etiolated-1 regulates c-Jun by assembling a CUL4A ubiquitin ligase. Science (2004) 3.28
Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A (2007) 3.13
Viral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantation. J Exp Med (2010) 3.09
Automated de novo protein sequencing of monoclonal antibodies. Nat Biotechnol (2008) 3.02
Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog (2007) 2.98
Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology (2005) 2.93
Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol (2005) 2.85
Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J Virol (2006) 2.68
Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell (2004) 2.60
Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol (2006) 2.55
Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J Virol (2002) 2.53
K11-linked polyubiquitination in cell cycle control revealed by a K11 linkage-specific antibody. Mol Cell (2010) 2.52
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol (2012) 2.43
Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1. Mol Cell Biol (2009) 2.26
Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial. BMJ (2012) 2.23
Thermodynamic and phylogenetic prediction of RNA secondary structures in the coding region of hepatitis C virus. RNA (2002) 2.20
The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res (2012) 2.19
High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J Mol Biol (2004) 2.14
A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell (2011) 2.14
Oncogenic ERBB3 mutations in human cancers. Cancer Cell (2013) 2.06
ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha vbeta 3 and induces blood vessel formation in vivo. J Biol Chem (2002) 2.02
Autophosphorylated CaMKIIalpha acts as a scaffold to recruit proteasomes to dendritic spines. Cell (2010) 2.02
Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. J Virol (2006) 1.99
Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res (2010) 1.98
The metabolic syndrome and CVD outcomes for a central Australian cohort. Diabetes Res Clin Pract (2013) 1.97
Assessing quality of diabetes care and its variation in Aboriginal community health centres in Australia. Diabetes Metab Res Rev (2010) 1.96
Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2(1). Biochem J (2009) 1.94
Engineering and structural characterization of a linear polyubiquitin-specific antibody. J Mol Biol (2011) 1.93
An Australian guideline for rheumatic fever and rheumatic heart disease: an abridged outline. Med J Aust (2007) 1.92
Phosphorylation of NLRC4 is critical for inflammasome activation. Nature (2012) 1.92
Broadly neutralizing human monoclonal antibodies to the hepatitis C virus E2 glycoprotein. J Gen Virol (2008) 1.91
Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology (2006) 1.88
Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem (2004) 1.88
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol (2009) 1.87
COP1 is a tumour suppressor that causes degradation of ETS transcription factors. Nature (2011) 1.83
Kinetics of hedgehog-dependent full-length Gli3 accumulation in primary cilia and subsequent degradation. Mol Cell Biol (2010) 1.81
Human monoclonal antibodies to a novel cluster of conformational epitopes on HCV E2 with resistance to neutralization escape in a genotype 2a isolate. PLoS Pathog (2012) 1.79
HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Hum Mol Genet (2002) 1.79
Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J Virol (2007) 1.77
Echocardiographic screening for rheumatic heart disease in high and low risk Australian children. Circulation (2014) 1.76
PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell (2010) 1.75
Measuring the gap-it may well be worse than we thought. Heart Lung Circ (2010) 1.74
Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol (2006) 1.71
The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus. J Virol (2008) 1.70
Structure-function studies of two synthetic anti-vascular endothelial growth factor Fabs and comparison with the Avastin Fab. J Biol Chem (2005) 1.69
Establishment and maintenance of gammaherpesvirus latency are independent of infective dose and route of infection. J Virol (2003) 1.67
Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol (2006) 1.66
Definition of a conserved immunodominant domain on hepatitis C virus E2 glycoprotein by neutralizing human monoclonal antibodies. J Virol (2008) 1.63
Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol (2010) 1.59
Human DDX3 functions in translation and interacts with the translation initiation factor eIF3. Nucleic Acids Res (2008) 1.57
Impact of the learning curve for endoscopic vein harvest on conduit quality and early graft patency. Ann Thorac Surg (2011) 1.56
Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. J Mol Biol (2004) 1.53
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature (2013) 1.52
Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel. Hepatology (2008) 1.49
Antibody to a lytic cycle viral protein decreases gammaherpesvirus latency in B-cell-deficient mice. J Virol (2002) 1.48
Recognition of UbcH5c and the nucleosome by the Bmi1/Ring1b ubiquitin ligase complex. EMBO J (2011) 1.48
Ubiquitin ligase RNF146 regulates tankyrase and Axin to promote Wnt signaling. PLoS One (2011) 1.46
Improved quantitative mass spectrometry methods for characterizing complex ubiquitin signals. Mol Cell Proteomics (2010) 1.43
Phosphorylation-dependent activity of the deubiquitinase DUBA. Nat Struct Mol Biol (2012) 1.42
A strategy for risk mitigation of antibodies with fast clearance. MAbs (2013) 1.42
Ubiquitin binding to A20 ZnF4 is required for modulation of NF-κB signaling. Mol Cell (2010) 1.41
Long-term surveillance of cefotaxime and piperacillin-tazobactam prescribing and incidence of Clostridium difficile diarrhoea. J Antimicrob Chemother (2004) 1.39
Structures of APRIL-receptor complexes: like BCMA, TACI employs only a single cysteine-rich domain for high affinity ligand binding. J Biol Chem (2004) 1.38
Suppressor of fused regulates Gli activity through a dual binding mechanism. Mol Cell Biol (2004) 1.38
Phosphatidylserine receptor Tim-4 is essential for the maintenance of the homeostatic state of resident peritoneal macrophages. Proc Natl Acad Sci U S A (2010) 1.38
Herpes simplex virus type 1 portal protein UL6 interacts with the putative terminase subunits UL15 and UL28. J Virol (2003) 1.37
Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice. J Clin Invest (2010) 1.36
Critical role for a high-affinity chemokine-binding protein in gamma-herpesvirus-induced lethal meningitis. J Clin Invest (2002) 1.34
Study protocol: Audit and Best Practice for Chronic Disease Extension (ABCDE) Project. BMC Health Serv Res (2008) 1.30
Requirement of cellular DDX3 for hepatitis C virus replication is unrelated to its interaction with the viral core protein. J Gen Virol (2009) 1.30
EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation. Clin Cancer Res (2008) 1.30
Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1. J Biol Chem (2003) 1.29
Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library. J Mol Biol (2006) 1.29
Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol (2004) 1.29
Ten principles relevant to health research among Indigenous Australian populations. Med J Aust (2012) 1.28
Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. J Gen Virol (2007) 1.27
Lower than expected morbidity and mortality for an Australian Aboriginal population: 10-year follow-up in a decentralised community. Med J Aust (2008) 1.27
Tyrosine plays a dominant functional role in the paratope of a synthetic antibody derived from a four amino acid code. J Mol Biol (2005) 1.26
In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc Natl Acad Sci U S A (2008) 1.25
Cooperativity in virus neutralization by human monoclonal antibodies to two adjacent regions located at the amino terminus of hepatitis C virus E2 glycoprotein. J Virol (2012) 1.24
Replication-competent recombinant vesicular stomatitis virus encoding hepatitis C virus envelope proteins. J Virol (2007) 1.24
Structural basis for high-affinity HER2 receptor binding by an engineered protein. Proc Natl Acad Sci U S A (2010) 1.24